news

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...

Oct 10, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...

Oct 8, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for...

Oct 2, 2024

Presentations

Events & Presentations

Corporate Presentation

LPCN 1154 for Depression R&D Event, July 9th 2025

LPCN 1154 Topline Results – PK Bridge Clinical Study

LPCN 1154 – Oral Bioidentical Neuroactive Steroid (NAS) for PPD

LPCN 1154: Oral Neuroactive Steroid for Depression Disorders

LPCN 2401 for Obesity Management

KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management

LPCN 2401 for Obesity Management

LPCN 1148 Management of Liver Cirrhosis

LPCN 1148 Presentation

LPCN 1148 Phase 2 Study Topline Results

AASLD Poster 11/13/2023

AASLD Presentation 11/13/2023

EASL Congress Presentation

LPCN 2101 Neuroactive Steroid for Epilepsy

LPCN 2101 Endogenous Neuroactive Steroid for Epilepsy

LPCN 1107 Pioneering A Convenient Solution to the Preterm Birth Health Crisis

LPCN 1144 Presentation

LPCN 1144 LiFT 12 Week Study Results

LPCN 1144 Presentation-LiFT Topline 36 Week Results

LPCN 1144 Presentation-OLE Topline Results

LPCN 1144 for Nonalcoholic Steatohepatitis (NASH)

LPCN 1111 Once Daily Oral Testosterone

TLANDO® (LPCN 1021) The Convenient Oral Testosterone Replacement Therapy without Titration Requirement

Focus on enhancing health

We are pioneers of developing innovative drug products targeting significant unmet medical needs.